Beyond the Window: Patient Characteristics and Geographic Locations Associated with Late Prenatal Care in Women Eligible for 17-P Preterm Birth Prevention
To reduce the risk of recurrence, women with a history of spontaneous preterm birth (PTB) are recommended to receive 17-hydroxyprogesterone caproate (17-P) injections starting by the 20th week of pregnancy. In women eligible for 17-P, we aimed to identify patient factors and geospatial locations associated with increased risk of presentation beyond 20 weeks gestation.
We conducted a secondary analysis of a retrospective cohort study including all women meeting criteria for 17-P within a single academic medical center over a 2-year period. We compared early (< 20 6/7 weeks) with late (> 21 weeks) presenters via demographics, social history, and index pregnancy outcomes using standard and Bayesian statistical models. Geospatial mapping was performed to determine residential areas with high risk for late presentation.
Geocoded address data was available for 351 women in whom the mean gestational age at first visit was 14.9 weeks, and 63 of whom were late presenters (17.9%). Younger maternal age, current smoking, and lack of health insurance were predictors of late presentation with greater than 95% probability. Hispanic ethnicity and black race were associated with higher odds of late presentation with 87 and 69% probability, respectively. The area with the latest gestational age at presentation was located within central Durham City and to the northeast.
Our study identified patient-level risk factors and geographic locations associated with presentation beyond the recommend window for 17-P initiation. These findings suggest an urgent need for intervention to improve early prenatal care initiation and a target location where such interventions will be most impactful.
Keywords17-P 17-hydroxyprogesterone caproate Disparity Preterm birth
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The retrospective cohort and the current analysis were approved by Duke IRB (Pro00067663). This article does not contain any studies with animals performed by any of the authors.
- 4.Crane SS, Naples R, Grand CK, Friebert S, McNinch N, Kantak A, et al. Assessment of adherence to guidelines for using progesterone to prevent recurrent preterm birth. J Matern Fetal Neonatal Med. 2016;29:1861–5.Google Scholar
- 6.DeNoble ea. Factors affecting utilization and effectiveness of 17-hydroxyprogesterone caproate for the prevention of recurrent preterm brith. In revision at Am J Perinatology. (Personal Communication). 2017 (In revision).Google Scholar
- 8.Knighton AJ, Savitz L, Belnap T, et al. Introduction of an Area Deprivation Index measuring patient socioeconomic status in an integrated health system: implications for population health. EGEMS (Wash DC). 2016;4:1238.Google Scholar
- 9.Program UHI. Health Innovation Program. Area Deprivation Index. UW Health Innovation Program; 2014. 2014 [cited 2018 March 16]; Available fromGoogle Scholar
- 10.Wood S. Package ‘mgcv’: Mixed GAM Computation Vehicle with GCV/AIC/REML Smoothness Estimation. [cited 2017 May 29]; Available from: https://cran.r-project.org/web/packages/mgcv/mgcv.pdf.
- 15.American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Guidelines for perinatal care. Eighth ed. Washington, DC: American Academy of Pediatrics; The American College of Obstetricians and Gynecologists; 2017.Google Scholar
- 16.PeriStats. [cited 2018 June 10]; Available from:www.marchofdimes.org/Peristats.
- 17.Baer RJ, Altman MR, Oltman SP, Ryckman KK, Chambers CD, Rand L, et al. Maternal factors influencing late entry into prenatal care: a stratified analysis by race or ethnicity and insurance status. J Matern Fetal Neonatal Med. 2018:1–7.Google Scholar
- 18.Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: final data for 2014. Natl Vital Stat Rep. 2016;65:1–122.Google Scholar
- 20.Mason MV, Poole-Yaeger A, Krueger CR, House KM, Lucas B. Impact of 17P usage on NICU admissions in a managed medicaid population—a five-year review. Manag Care. 2010;19:46–52.Google Scholar
- 21.Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH,Spong CY, et al., National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379–2385.Google Scholar